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Abstract
On 24th March, the world commemorates the day in 1882 when Dr Robert
Koch announced his discovery of   (MTB). OverMycobacterium tuberculosis
130 years later, tuberculosis (TB) continues to affect individuals, communities,
and entire health systems and economies. Koch unsuccessfully tried to ‘cure’
TB, and despite major advances in other areas of medicine, control of TB
remains elusive- in 2016 TB was the leading infectious cause of death. The
STOP TB partnership and World Health Organization (WHO) have announced
their theme for World TB Day 2018 “Wanted: Leaders for a TB-Free World. You
can make history. End TB.” This theme recognizes that TB is much larger than
any one person, institute or discipline of research, and provides an opportunity
for us to reflect on the major challenges and consider how we, as a scientific
community, can work together and take the lead to address the global crisis of
drug-resistant TB (DR-TB).
 
This article is included in the World TB Day
collection.
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What is drug resistant TB, where is it and how is it 
spread?
Resistance to key first-line anti-TB drugs manifests most com-
monly as rifampicin-resistant and multi-drug resistant (MDR) 
TB, and continues to increase despite overall global reductions 
in TB incidence. The gap between notified cases (~150,000 glo-
bally in 2016) and estimated burden (~600,000 globally) also 
widens1. More concerningly, global estimates indicate that only 
1 in 10 patients with MDR-TB are successfully treated. It is not 
coincidence that the highest drug-resistant TB (DR-TB) burden 
concentrates in the parts of Europe, Africa and Asia with the weak-
est health systems, and reflects failures at all stages of the DR-
TB care pathway, including seeking care, diagnosis of TB and 
drug-resistance, and supporting a long, and often toxic treatment 
regimen.
Furthermore, we are only recently beginning to understand 
the impact that failing to control DR-TB has on onward trans-
mission, with potentially devastating consequences. Whereas 
strengthening the delivery of drug-sensitive TB care was a prior-
ity for managing DR-TB through prevention of de novo resistance, 
other strategies will be required to deal with the ongoing trans-
mission of DR-TB. There are still too many unknowns in our 
understanding of how much and where DR-TB occurs, and how 
it spreads.
What are we doing about drug resistant TB?
This is not to say there hasn’t been progress in managing 
DR-TB. Traditionally, diagnosis of DR-TB required culture and 
drug-susceptibility testing, with very long turnaround times, 
and lack of facilities and expertise where the need was greatest, 
contributing to under-diagnosis and pre-treatment loss-to-care. 
However, the development and scaling-up of near patient molec-
ular testing technologies, for example the Xpert MTB/RIF assay 
(Cepheid, USA), has already been utilized to accurately detect 
rifampicin-resistance, with promising progress in detecting 
second-line drug (mainly fluoroquinolones and aminoglycosides) 
susceptibility using similar technologies.
Existing treatments for DR-TB are lengthy, require patients to 
take tens of pills and attend health facilities for injections, have 
modest efficacy and commonly cause debilitating side-effects. 
The first new anti-TB drugs for over 40 years – delamanid and 
bedaquiline – have been reserved for DR-TB. Data emerging from 
observational and randomized studies suggests good outcomes can 
be achieved with shorter regimens and fewer drugs. Combining 
these with improved diagnostics offers some hope of improving 
successful treatment completion rates.
Molecular techniques and whole-genome sequencing have also 
improved understanding of DR-TB transmission, and genomic 
evidence strongly supports transmission of DR strains in mul-
tiple settings. Yet the evidence on how to manage contacts of 
DR-TB who have potentially been exposed is still lacking, 
especially those at highest risk, for example children or people 
living with HIV. Randomized trials of preventive drug therapies 
are ongoing. We have also begun to describe the catastrophic costs 
and impact of DR-TB on individuals, families, communities and 
health systems, as, even highly efficacious interventions cannot be 
delivered successfully without addressing these2.
What new approaches should we consider?
Our understanding of the TB bacillus has progressed since Koch’s 
discovery. Despite MTB’s genome being first sequenced in 1998, 
many questions remain unanswered about both the pathogen 
and host-pathogen interactions. Although it is clear that MTB 
utilizes and manipulates human host responses to facilitate its 
survival and onward transmission, our understanding of how to 
influence these interactions for prevention of infection and/or 
disease is incomplete. 
Identifying the immunological correlates of protection and 
pathogenesis is a key priority in TB research. This knowledge is 
crucial to inform development of host directed therapies which 
may improve outcomes and shorten treatment duration, espe-
cially in TB which is also resistant to second-line therapies, and 
could also be applied to the design of effective vaccines and to 
better target treatment of latent TB. Evidence from both human and 
animal studies suggests that the most effective immune responses 
in TB comprise inflammation to control the bacteria balanced by 
regulatory mechanisms that prevent damage to the tissues3, but 
the molecular details of how this balancing act is achieved are 
incompletely understood.
In order to elucidate the molecular mechanisms that lead to favora-
ble outcomes, it is essential to faithfully model immune responses 
at the site of TB disease, more specifically within the granuloma, 
where key interactions between host and pathogen take place. 
Advances in genome editing techniques now provide unprec-
Editorial:
TB was declared a global emergency in 1993 and great efforts 
have been made to improve cure rates and reduce mortality from 
drug-sensitive tuberculosis. However, the widespread emergence 
of DR-TB threatens to overthrow decades of progress. TB is 
the most widespread airborne anti-microbial resistant (AMR) 
disease worldwide and, in September 2017, the WHO declared 
TB a priority pathogen for the development of new antibiotics. 
The pressure of coping with drug resistant TB on patients, health 
systems and economies is magnitudes of scale greater than that 
of drug sensitive TB, which is itself already a huge burden. The 
problem has been amplified by decades of under investment in 
TB research and development which has left us with knowledge 
gaps and limited tools to deal with this new threat.
Questions we would like the scientific community to reflect on for 
World TB Day 2018 include: 
1) What is drug resistant TB, where is it and how is it spread?
2) What are we doing about drug-resistant TB?
3) What new approaches should we consider?
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edented opportunities to investigate the influence of identified 
candidate genes or pathways by genetic manipulation in tractable 
animal models. Ultimately, these strategies are expected to iden-
tify pathways that represent novel therapeutic targets or biomar-
kers that could be applied to improve diagnosis, design effective 
personalized treatment plans and monitor clinical response to 
therapy.
Whilst eagerly awaiting new interventions emerging from a bet-
ter understanding of pathogenesis, we also need to address the 
issues of inequality, human rights and social protection that 
underpin the TB, and DR-TB, epidemic. DR-TB disproportion-
ately effects underserved populations, for example those of lower-
socioeconomic status, people living with HIV, those living further 
away from health facilities and those who inject drugs. These 
factors strongly contribute to the burden of undiagnosed DR-TB 
and the inability to successfully complete treatment, leading to 
individual morbidity and mortality as well as ongoing transmission. 
A better understanding of how health systems, social and finan-
cial interventions can support DR-TB prevention and treatment 
is desperately needed.
Hope for the future
In 2018 we have some hope for the future. In the UK we are 
moving into an era where whole-genome sequencing is used in 
clinical practice to rapidly assess the drug sensitivity of myco-
bacteria and provide a highly detailed picture of transmission. 
The Nix-TB regimen, which combines pretomanid, bedaquiline 
and linezolid (ClinicalTrials.gov Identifier: NCT02333799) offers 
the possibility of an effective 6-month treatment for all forms 
of drug resistant TB4. There will also be a United Nations General 
Assembly, high-level meeting on TB taking place in 2018. This 
will be the first-ever high-level meeting on TB and the presence 
and commitment of heads-of-state will be fundamental to stimulate 
and drive efforts to control TB.
The TB community can learn lessons from the HIV commu-
nity in the unified way that they responded to HIV. The quote 
below could equally apply to our response to DR-TB. The future 
lies in a concerted and integrated response to this threat which 
is focused not just on the mycobacteria but also the patient, the 
economy and the health systems that carry the burden of dealing 
with DR-TB.
“our most precious contribution may well be that at the time 
of the plague we did not flee; we did not hide; and we did not 
separate.”- Jonathan Mann.
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